Intermediate acting versus long acting insulin for type 1 diabetes mellitus-Reference-Cited by-同舟云学术

Intermediate acting versus long acting insulin for type 1 diabetes mellitus

Published:2008-07-16 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Vardi Moshe¹,Jacobson Eyal²,Nini Asaph³,Bitterman Haim⁴

Affiliation:

1. Carmel Medical Center; Internal Medicine; 7 Michal St, Haifa Haifa Israel 34362

2. Clalit Health Services, Haifa and Western Galilee District; Department of Family Medicine; 6 Shahaf Street Haifa Israel 35013

3. Sheba Medical Center; Intensive Care Unit; 2 Sheba Rd Tel Hashomer Israel 52661

4. Carmel Lady Davis Medical Center; Internal Medicine; 7 Michal Street Haifa Israel 34362

Publisher

Wiley

Subject

Pharmacology (medical)

Reference66 articles.

1. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes;Ashwell;Diabetic Medicine,2006

2. Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes-The glargine and aspart study (GLASS). A randomised cross-over study;Chatterjee;Diabetes Research and Clinical Practice,2006

3. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin;De;Diabetes, Obesity & Metabolism,2005

4. Human ultralente insulin: A comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia;Francis;Diabetes Research,1986

5. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy;Fulcher;Internal Medicine Journal,2005

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes Management in Transition: Market Insights and Technological Advancements in CGM and Insulin Delivery;Advanced Sensor Research;2024-07-11

2. Therapy for Type 1 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-02-16

3. Therapie des Typ-1-Diabetes – Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057-013; 4. Auflage 2018);Diabetologie und Stoffwechsel;2023-10

4. Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs;Pharmaceutics;2023-09-01

5. Treatment of type 1 diabetes;Die Diabetologie;2023-05-08